Citius Pharmaceuticals EBITDA 2011-2026 | CTXR

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Citius Pharmaceuticals

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-42 M	-36.7 M	-33.3 M	-23.5 M	-17.4 M	-15.6 M	-13.8 M	-9.98 M	-7.45 M	-3.23 M	-	-28.1 K	-19.6 K	-24.9 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-19.6 K	-42 M	-15.6 M

Quarterly EBITDA Citius Pharmaceuticals

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-9.34 M	-	-	-	-7.25 M	-25.8 M	-8.92 M	-7.59 M	-9.26 M	-18.3 M	-5.98 M	-4.19 M	-8.16 M	-13.6 M	-4.69 M	-8.16 M	-4.45 M	-11.9 M	-4.43 M	-4.45 M	-3.87 M	-10.1 M	-2.02 M	-3.87 M	-3.24 M	-7.58 M	-2.25 M	-3.24 M	-2.78 M	-	-2.13 M	-2.78 M	-1.24 M	-2.26 M	-774 K	-1.24 M	-879 K	-550 K	-1.3 K	-879 K	-499 K	-13.4 K	-3.44 K	-298	-636	-15.1 K	-6.18 K	-636	-2.2 K	-23.2 K	-7.1 K	-2.2 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-298	-25.8 M	-4.35 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
AgeX Therapeutics AGE	-23.9 M	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Exelixis EXEL	901 M	$ 48.43	9.03 %	$ 13.2 B	USA
Fortress Biotech FBIO	-69.8 M	$ 2.56	3.96 %	$ 71.4 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Galapagos NV GLPG	-166 M	$ 28.78	1.36 %	$ 2.69 B	Belgium
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Genmab A/S GMAB	6.57 B	$ 27.93	1.41 %	$ 17.2 B	Danmark
Genprex GNPX	-21.2 M	$ 0.9	2.02 %	$ 839 K	USA
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Grifols, S.A. GRFS	595 M	$ 8.41	1.69 %	$ 6.83 B	Spain
Athira Pharma ATHA	-101 M	-	-	$ 269 M	USA
InflaRx N.V. IFRX	-37.3 M	$ 2.47	25.39 %	$ 152 M	Germany
Ionis Pharmaceuticals IONS	-204 M	$ 76.96	2.27 %	$ 12.3 B	USA
Kamada Ltd. KMDA	-696 K	$ 8.3	1.1 %	$ 260 M	Israel
BioNTech SE BNTX	15.3 B	$ 95.07	-0.45 %	$ 27.2 B	Germany
Kymera Therapeutics KYMR	-341 M	$ 86.14	4.15 %	$ 7.28 B	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Checkmate Pharmaceuticals CMPI	-61.4 M	-	-	$ 231 M	USA
Ligand Pharmaceuticals Incorporated LGND	12.6 M	$ 229.83	-1.06 %	$ 4.2 B	USA
INmune Bio INMB	-47.3 M	$ 1.52	-1.3 %	$ 37.6 M	USA
Liquidia Corporation LQDA	-49.8 M	$ 41.84	4.26 %	$ 3.6 B	USA
Mirum Pharmaceuticals MIRM	2.11 M	$ 107.42	1.52 %	$ 5.39 B	USA
ACADIA Pharmaceuticals ACAD	232 M	$ 22.32	-0.13 %	$ 3.7 B	USA
MannKind Corporation MNKD	51.1 M	$ 3.68	28.5 %	$ 1.12 B	USA
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Nanobiotix S.A. NBTX	-52.6 M	$ 42.28	21.6 %	$ 286 B	France
Esperion Therapeutics ESPR	60.4 M	$ 3.13	0.55 %	$ 651 M	USA
Can-Fite BioPharma Ltd. CANF	-9.93 M	$ 3.47	-8.44 %	$ 5.71 M	Israel
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-55.6 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Aptose Biosciences APTO	22 K	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	-62.4 M	-	-39.0 %	$ 4.57 M	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Allakos ALLK	-190 M	-	-	$ 28.6 M	USA
AlloVir ALVR	-46.1 M	-	4.14 %	$ 49.1 M	USA
Arcutis Biotherapeutics ARQT	-11.5 M	$ 23.86	1.88 %	$ 3.04 B	USA
Allena Pharmaceuticals ALNA	-47.3 M	-	3.16 %	$ 1.9 M	USA
Puma Biotechnology PBYI	48.2 M	$ 7.5	2.04 %	$ 375 M	USA
Ampio Pharmaceuticals AMPE	122 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
Alpine Immune Sciences ALPN	-57.6 M	-	-	$ 2.17 B	USA